Zogenix, Inc.
Zogenix, Inc., a prominent biopharmaceutical company headquartered in the United States, focuses on developing and commercialising innovative therapies for patients with rare neurological diseases. Founded in 2013, Zogenix has made significant strides in the industry, particularly with its flagship product, Fintepla, which is designed to treat Dravet syndrome, a severe form of epilepsy. With a commitment to addressing unmet medical needs, Zogenix operates primarily in the US and has expanded its reach to international markets. The company is recognised for its unique approach to drug development, leveraging advanced formulations to enhance patient outcomes. Zogenix's dedication to innovation and patient care has solidified its position as a leader in the biopharmaceutical sector, earning accolades for its contributions to the treatment of complex neurological disorders.
DitchCarbon Score
How does Zogenix, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zogenix, Inc.'s score of 23 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Zogenix, Inc.'s reported carbon emissions
Zogenix, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. As a result, there are no reported figures for their Scope 1, 2, or 3 emissions. The company has not outlined any formal climate commitments or initiatives aimed at reducing carbon emissions. In the absence of specific data, it is unclear how Zogenix is addressing climate change or contributing to sustainability efforts within the pharmaceutical industry.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zogenix, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
